Found: 14
Select item for more details and to access through your institution.
Transcriptome analysis in patients with temporal lobe epilepsy.
- Published in:
- 2019
- By:
- Publication type:
- journal article
High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer.
- Published in:
- NPJ Genomic Medicine, 2019, v. 4, n. 1, p. N.PAG, doi. 10.1038/s41525-019-0087-6
- By:
- Publication type:
- Article
A Comparison of Tools for Copy-Number Variation Detection in Germline Whole Exome and Whole Genome Sequencing Data.
- Published in:
- Cancers, 2021, v. 13, n. 24, p. 6283, doi. 10.3390/cancers13246283
- By:
- Publication type:
- Article
Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study.
- Published in:
- Molecular Oncology, 2022, v. 16, n. 1, p. 206, doi. 10.1002/1878-0261.13015
- By:
- Publication type:
- Article
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10632-9
- By:
- Publication type:
- Article
GENE-30. INCREASED TUMOR MUTATIONAL LOAD AFTER RADIOTHERAPY AND TEMOZOLOMIDE IN PROGRESSING GLIOBLASTOMA A PROSPECTIVE STUDY.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi109, doi. 10.1093/neuonc/noy148.456
- By:
- Publication type:
- Article
Characterization of somatic mutations in sporadic uveal melanoma and uveal melanoma in patients with germline BAP1 pathogenic variants.
- Published in:
- PLoS ONE, 2024, v. 19, n. 10, p. 1, doi. 10.1371/journal.pone.0306386
- By:
- Publication type:
- Article
Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact.
- Published in:
- Acta Oncologica, 2022, v. 61, n. 12, p. 1499, doi. 10.1080/0284186X.2022.2156809
- By:
- Publication type:
- Article
Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.
- Published in:
- 2020
- By:
- Publication type:
- Case Study
A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
- Published in:
- BMC Cancer, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12885-022-10420-x
- By:
- Publication type:
- Article
A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
- Published in:
- BMC Cancer, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12885-022-10420-x
- By:
- Publication type:
- Article
Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy.
- Published in:
- Frontiers in Genetics, 2023, v. 14, p. 1, doi. 10.3389/fgene.2023.1058605
- By:
- Publication type:
- Article
Immunotherapy drives mesenchymal tumor cell state shift and TME immune response in glioblastoma patients.
- Published in:
- Neuro-Oncology, 2024, v. 26, n. 8, p. 1453, doi. 10.1093/neuonc/noae085
- By:
- Publication type:
- Article